Becton Dickinson & Co Stock Price, News & Analysis

BD (Becton, Dickinson and Company) announced a remediation effort for the BD Alaris™ System, addressing issues related to a voluntary recall from February 4, 2020. Software version 12.1.2 will be released at no cost to customers to resolve software errors, including delay options programming and low battery alarm failures. While the remediation aims to enhance operational and cybersecurity aspects, it is important to note that this update has not yet been reviewed by the FDA. The company has also submitted a 510(k) application for regulatory clearance regarding the updates made to the product.

BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.83 per common share, payable on September 30, 2021, with a record date of September 9, 2021. This sets the annual dividend rate at $3.32 per share, reflecting the company's commitment to delivering value to its shareholders. BD continues to be a leader in the medical technology sector, providing innovative solutions to enhance healthcare delivery globally.

BD (Becton, Dickinson and Company) announced its acquisition of Tepha, Inc., a developer of proprietary resorbable polymer technology, aimed at enhancing BD's surgical mesh portfolio. This acquisition facilitates vertical integration of the supply chain for BD's Phasix™ Mesh products. Tepha's GalaFLEX® products will bolster BD's capabilities in soft tissue repair and regeneration. The deal, expected to have an immaterial impact on BD's fiscal 2021 financial results, underscores the company's commitment to innovation in medical technology and enhancement of surgical solutions.

On July 23, 2021, a federal jury in Dallas found C.R. Bard's IVC blood clot filter defective, adding to a total of over $7 million in awards against the company. This marks the fourth jury ruling against Bard regarding these filters, which are linked to serious medical complications. The Recovery IVC filter caused significant issues when it fractured post-implantation. Lawyers representing affected individuals expressed intentions to continue pursuing cases until Bard acknowledges its responsibility for the product's safety risks.

BD (Becton, Dickinson and Company) has announced its acquisition of Velano Vascular, aiming to enhance patient experience through its 'One-Stick Hospital Stay' vision. This innovative approach utilizes Velano's PIVO™ device, allowing blood collection via existing PIVC lines, potentially reducing the need for multiple needlesticks. The initiative aligns with BD's long history of improving blood collection and vascular access. This acquisition supports BD's growth strategy to address unmet needs in healthcare. Financial terms of the acquisition were not disclosed.

On July 12, 2021, BD announced the appointment of David F. Melcher as non-executive chair and Claire Pomeroy as a director for its upcoming Diabetes Care spinoff, expected in H1 2022. The spinoff, subject to customary approvals, aims to establish a standalone entity poised for growth in the diabetes sector. Melcher brings extensive leadership experience, while Pomeroy offers insights from health care delivery. The transition is critical for NewCo, positioned as a major force in diabetes care.

BD (Becton, Dickinson and Company) has launched a new eCommerce platform at bdbiosciences.com aimed at enhancing the online purchasing experience for flow cytometry users. The website offers over 170 pages of new content, improved search capabilities, and customized dashboards for streamlined purchases. Available in the U.S., Canada, Europe, Australia, and New Zealand, the platform integrates with procurement systems, ensuring institutional pricing and approval processes are simplified. BD aims to empower researchers and lab managers by addressing their purchasing needs effectively.

BD (Becton, Dickinson and Company) will announce its third quarter fiscal 2021 financial results on August 5, 2021, at approximately 6:00 a.m. ET. A conference call will follow at 8:00 a.m. ET for discussions on the results, operations, and strategy. The event will be available for replay until August 12, 2021. Additionally, BD plans to host an Investor Day on November 12, 2021, with more details to be shared later. For further information, visit bd.com/investors.

BD (Becton, Dickinson and Company) announced it received 510(k) clearance from the FDA for its PeritX™ Peritoneal Catheter System to drain symptomatic, recurrent non-malignant ascites. This system, which expands on the existing PleurX™ system, allows patients to manage their condition at home, reducing hospital visits. The PeritX™ is now the first FDA-approved tunneled catheter for both malignant and non-malignant ascites, improving patient care and comfort.